Disease activity parameters in axSpA patients at baseline and 6 and 12 months post-switch from originator adalimumab to adalimumab-AACF
Disease activity parameters at baseline and after switching
Baseline (n = 28)
6 months (n = 27)
P
12 months (n = 27)
P
ASDAS-CRP
1.56 (± 0.88)
1.50 (± 0.82)
0.732
1.26 (± 0.86)
0.133
ASDAS-ESR
1.47 (± 0.93)
1.57 (± 0.78)
0.876
1.27 (± 0.87)
0.979
BASDAI
1.30 (± 1.43)
1.26 (± 1.63)
0.176
0.99 (± 1.28)
0.331
CRP (mg/L)
3.9 (1.9; 8.1)
2.6 (1.8; 4.9)
0.310
2.6 (1.63; 6.9)
0.494
Data are presented as mean (± standard deviation) or median (interquartile range); statistical significance was considered when P < 0.05. axSpA: axial spondyloarthritis; ASDAS-CRP: Ankylosing Spondylitis Disease Activity Score-C-reactive protein; ASDAS-ESR: Ankylosing Spondylitis Disease Activity Score-erythrocyte sedimentation rate; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index
Declarations
Author contributions
FARN and BB: Conceptualization, Investigation, Writing—original draft. KRB and NEA: Conceptualization, Investigation, Writing—review & editing. APLA, FHCdS, CEI, HAMG and EFVNY: Investigation, Validation, Writing—review & editing. RM: Investigation, Writing—review & editing. EB: Conceptualization, Validation, Writing—review & editing, Supervision. CGSS and ACdMR: Conceptualization, Investigation, Writing—review & editing, Supervision. JCBdM and AYS: Conceptualization, Investigation, Writing—original draft, Writing—review & editing, Supervision. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This study was approved by the Local Ethics Committee on Human Research of the University of São Paulo (CAPPesq), under number 1298/06.
Consent to participate
Informed consent to participate in the study was obtained from all participants.
Consent to publication
Not applicable.
Availability of data and materials
The raw data supporting the conclusions of this manuscript will be made available by the authors, without undue reservation, to any qualified researcher.
Funding
This work was supported by grants from Fundacao de Amparo a Pesquisa do Estado de São Paulo [FAPESP #2015/03756-4 to E.B.]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico [CNPq grants #305068/2014-8 to E.B.]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.
References
Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.Ann Rheum Dis. 2023;82:19–34. [DOI] [PubMed]
Webers C, Ortolan A, Sepriano A, Falzon L, Baraliakos X, Landewé RBM, et al. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.Ann Rheum Dis. 2023;82:130–41. [DOI] [PubMed]
Smolen JS, Caporali R, Doerner T, Fautrel B, Benedetti F, Pieper B, et al. Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.RMD Open. 2021;7:e001637. [DOI] [PubMed] [PMC]
Jha A, Upton A, Dunlop WCN, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.Adv Ther. 2015;32:742–56. [DOI] [PubMed] [PMC]
García-Beloso N, Altabás-González I, Samartín-Ucha M, Gayoso-Rey M, De Castro-Parga ML, Salgado-Barreira Á, et al. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review.Br J Clin Pharmacol. 2022;88:1529–50. [DOI] [PubMed]
Schmalzing M, Kellner H, Askari A, Santos JDT, Perez-Coleman JCV, Foti R, et al. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.Adv Ther. 2024;41:315–30. [DOI] [PubMed] [PMC]
Kapoor S, Kaushik VV, Jain R, Rao VKR, Gharia M. Real-life Tolerability and Effectiveness of Adalimumab Biosimilar in Ankylosing Spondylitis: the Adalimumab Biosimilar Patient Registry Data.ACR Open Rheumatol. 2019;1:480–4. [DOI] [PubMed] [PMC]
Baji P, Péntek M, Szántó S, Géher P, Gulácsi L, Balogh O, et al. Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis.Eur J Health Econ. 2014;15:45–52. [DOI] [PubMed] [PMC]
Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.Ann Rheum Dis. 2019;78:192–200. [DOI] [PubMed]
Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.Ann Rheum Dis. 2013;72:1605–12. [DOI] [PubMed] [PMC]
Glintborg B, Sørensen IJ, Loft AG, Lindegaard H, Linauskas A, Hendricks O, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry.Ann Rheum Dis. 2017;76:1426–31. [DOI] [PubMed]
Li J, Xue Z, Wu Z, Bi L, Liu H, Wu L, et al. Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.Clin Rheumatol. 2022;41:3005–16. [DOI] [PubMed]
Xu H, Li Z, Wu J, Xing Q, Shi G, Li J, et al. IBI303, a biosimilar to adalimumab, for the treatment of patients with ankylosing spondylitis in China: a randomised, double-blind, phase 3 equivalence trial.Lancet Rheumatol. 2019;1:e35–43. [DOI] [PubMed]
Becciolini A, Parisi S, Caccavale R, Bravi E, Lumetti F, Andracco R, et al. Adalimumab and ABP 501 in the Treatment of a Large Cohort of Patients with Inflammatory Arthritis: A Real Life Retrospective Analysis.J Pers Med. 2022;12:335. [DOI] [PubMed] [PMC]
Müller-Ladner U, Dignass A, Gaffney K, Jadon D, Matucci-Cerinic M, Lobaton T, et al. The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune-Mediated Inflammatory Disease.BioDrugs. 2023;37:873–89. [DOI] [PubMed] [PMC]
Adrichem RCSv, Voorneveld HJE, Waverijn GJ, Kok MR, Bisoendial RJ. The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study.Rheumatol Ther. 2022;9:1109–18. [DOI] [PubMed] [PMC]
Bruni C, Bitti R, Nacci F, Cometi L, Tofani L, Bartoli F, et al. Efficacy and safety of switching from reference adalimumab to SB5 in a real-life cohort of inflammatory rheumatic joint diseases.Clin Rheumatol. 2021;40:85–91. [DOI] [PubMed]
Scrivo R, Castellani C, Mancuso S, Sciarra G, Giardina F, Bevignani G, et al. Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study.Clin Exp Rheumatol. 2023;41:613–9. [DOI] [PubMed]
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis.Ann Rheum Dis. 2009;68:ii1–44. [DOI] [PubMed]
Machado PMMC, Landewé RBM, Heijde DMvd. Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10.J Rheumatol. 2011;38:1502–6. [DOI] [PubMed]
Machado PM, Landewé R, Heijde DV; Assessment of SpondyloArthritis international Society (ASAS). Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states.Ann Rheum Dis. 2018;77:1539–40. [DOI] [PubMed]
Poddubnyy D, Sommerfleck F, Navarro-Compán V, Bundy C, Makri S, Akerkar S, et al. Regional differences in clinical phenotype of axial spondyloarthritis: results from the International Map of Axial Spondyloarthritis (IMAS).Rheumatology (Oxford). 2024;63:2328–35. [DOI] [PubMed] [PMC]
Kaneko K, Prieto-Alhambra D, Jacklin C, Bosworth A, Dickinson S, Berry S, et al. Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients’ satisfaction: a cross-sectional survey by patient organisations.BMJ Open. 2022;12:e050949. [DOI] [PubMed] [PMC]
Cantini F, Niccoli L, Franchi G, Damiani A, Benucci M. The Nocebo Effect in Rheumatology: An Unexplored Issue.Isr Med Assoc J. 2020;22:185–90. [PubMed]
